anti-CD20 therapy Archives - PharmaDeviceNews

What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis

By Soujanya Ravi on April 22, 2026 Pharma & Biotech

Explore how TG Therapeutics, Inc.’s BRIUMVI data at AAN 2026 could reshape real-world MS treatment and adoption trends. Read the full analysis now.

FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment

By Pallavi Madhiraju on April 21, 2026 Pharma & Biotech

FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.

What TG Therapeutics’ ACTRIMS strategy signals about the next competitive phase in anti-CD20 multiple sclerosis therapy

By Soujanya Ravi on February 6, 2026 Pharma & Biotech

Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.